Business Information
The group's principal activity is to develop and commercialize therapeutics for the treatment of life-threatening diseases. The group's lead product, zadaxin, is in two phase 3 hepatitis c clinical trials in the United States, a phase 3 hepatitis b clinical trial in Japan, a phase 2 malignant melanoma clinical trial in Europe and two phase 2 liver cancer trials in the United States. Zadaxin has been approved for sale in over 30 countries and is currently marketed in China and selected countries in Asia, Latin America and the Middle East. The group's other drug development opportunities include scv-07, an orally available therapy to treat viral and infectious diseases, as well as products to address the protein-based disorder that causes cystic fibrosis.
|
|
Name |
Title
|
Email
|
| Dean Woodman | Chmn. | N/A | | John Baxter | Dir., Chmn., Sciclone's Scientific Advisory Board | N/A | | Hans Schmid | MD - Sciclone Pharmaceuticals International, Ltd | N/A | | Cynthia Tuthill | Sr. VP - Scientific Affairs, Chief Scientific Officer | N/A | | Israel Rios | Chief Medical Officer | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 32,662 | 727 | | 2005 | 28,334 | (7,713) | | 2004 | 24,396 | (13,278)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
